Although MEK inhibitors have demonstrated limited efficacy as monotherapy in ccRCC, preclinical and early-phase clinical studies have begun to explore combination approaches, such as MEK inhibitors with VEGF inhibitors or immune checkpoint blockade, with modest results reported to date [30]. Here, MAP2K7 is linked to nonpapillary renal cell carcinoma.